Specialty Pharmacy Program Updates

Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications:

Indication  Coverage  Available From
Tepmetko (tepotinib)  Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.  Pharmacy  Biologics by McKesson
Ukoniq (umbralisib)  Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL).  Pharmacy  Onco360
Fotivda (tivozanib)  Treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.  Pharmacy  Onco360
Hetlioz (tasimelteon)  Treatment of nighttime sleep disturbances in SMS in pediatric patients 3-15 years of age.  Pharmacy  Diplomat
Nyvepria (pegfilgrastim-apgf)  Indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.  Pharmacy  CVS Specialty
Truseltiq (infigratinib)  Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.  Pharmacy
US Bioservices Specialty Pharmacy or Biologics by McKesson
Lumakras (sotorasib)  Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test.  Pharmacy  CVS Specialty
Enspryng (satralizumab) Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.  Pharmacy  CVS Specialty

Publication Information

Audrey Kleinberg,
Director, Provider Relations & Communications

Annmarie Dadoly,

Joseph O’Riordan,

Kristin Edmonston,
Production Coordinator